Computationally Selected Multivalent HIV-1 Subtype C Vaccine Protects Against Heterologous SHIV Challenge

Computationally Selected Multivalent HIV-1 Subtype C Vaccine Protects Against Heterologous SHIV Challenge

<b>Background</b>: The RV144 trial in Thailand is the only HIV-1 vaccine efficacy trial to date to demonstrate any efficacy. Genetic signatures suggested that antibodies targeting the variable loop 2 (V2) of the HIV-1 envelope played an important protective role. The ALVAC prime and prot...

Full description

Saved in:
Bibliographic Details
Main Authors: Dieter Mielke, Marina Tuyishime, Natasha S. Kelkar, Yunfei Wang, Robert Parks, Sampa Santra, Wes Rountree, LaTonya D. Williams, Tiffany Peters, Nathan Eisel, Sheetal Sawant, Lu Zhang, Derrick Goodman, Shalini Jha, Adam Zalaquett, Pratamesh Ramasubramanian, Sherry Stanfield-Oakley, Gary Matyas, Zoltan Beck, Mangala Rao, Julie Ake, Thomas N. Denny, David C. Montefiori, Margaret E. Ackerman, Lawrence Corey, Georgia D. Tomaras, Bette T. Korber, Barton F. Haynes, Xiaoying Shen, Guido Ferrari
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Vaccines
Subjects:
HIV-1
subtype C
variable loops 1 and 2
correlate of protection
systems serology
Online Access:https://www.mdpi.com/2076-393X/13/3/231
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items